CSIMarket Company Name, Ticker, Suppliers, else..
 

Adaptimmune Therapeutics Plc  (NASDAQ: ADAP)

Adaptimmune Therapeutics Plc's

Competitiveness



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

 

ADAP Sales vs. its Competitors Q2 2025


Comparing the current results to its competitors, Adaptimmune Therapeutics Plc reported Revenue decrease in the 2 quarter 2025 year on year by -89.33 %, despite the revenue increase by the most of its competitors of 4.21 %, recorded in the same quarter.

• List of ADAP Competitors





Revenue Growth Comparisons




Net Income Comparison

Adaptimmune Therapeutics Plc, slower than the average decrease reported by the company's competitors of -19.74 %. recorded a net loss and most of the company's competitors saw a decline in earnings by -19.74 %

<<  ADAP Stock Performance Comparisons





  

Overall company Market Share Q2 2025
Overall company, revenue fell by -89.33 % and company lost market share, to approximately 0.08 %.




<<  More on ADAP Market Share.
 
*Market share is calculated based on total revenue.





Publicly Traded Peers of Adaptimmune Therapeutics Plc




Zymeworks Inc
Share Performance



+11.16%
This Year
Zymeworks Inc
Profile

Zymeworks Inc is a biotechnology company that operates on a licensing and collaboration business model. They primarily generate revenue through partnerships and collaborations with pharmaceutical and biotechnology companies, providing access to their proprietary drug development platform and expertise in protein engineering. This enables them to advance the development of novel bi-specific antibodies and therapeutic proteins for the treatment of various diseases and medical conditions.

More about Zymeworks Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 2,210.218 mill. $ 81.263 mill. $ -102.656 mill.


Neximmune Inc
Share Performance



-50.00%
One Year
Neximmune Inc
Profile

Neximmune Inc is a biotechnology company that focuses on developing personalized immunotherapies to treat various cancers and autoimmune diseases.

More about Neximmune Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 0.000 mill. $ - mill. $ -20.617 mill.


Molecular Templates Inc
Share Performance



0.00%
30 Days
Molecular Templates Inc
Profile

Molecular Templates Inc's business model involves the development and commercialization of innovative biologic drugs based on their proprietary engineered toxin bodies (ETBs) platform.

More about Molecular Templates Inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 0.001 mill. $ 60.307 mill. $ -48.459 mill.


Marker Therapeutics inc
Share Performance



+8.61%
30 Days
Marker Therapeutics inc
Profile

Marker Therapeutics Inc is a biotechnology company that aims to develop and commercialize novel T cell immunotherapies for the treatment of cancer. Their business model focuses on leveraging their expertise in cellular engineering to develop proprietary technologies and therapies that can be licensed or partnered with other organizations for further development and commercialization.

More about Marker Therapeutics inc 's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 25.592 mill. $ - mill. $ -8.707 mill.


Meiragtx Holdings Plc
Share Performance



+79.77%
This Year
Meiragtx Holdings Plc
Profile

MeiraGTx Holdings Plc is a biotechnology company focused on developing gene therapies for inherited and acquired diseases. They leverage their proprietary technology to develop and commercialize innovative treatments that address unmet medical needs.

More about Meiragtx Holdings Plc's Market Share

Market Cap. Revenues TTM Net Income TTM
$ 1,141.465 mill. $ 79.758 mill. $ -120.533 mill.

51 more competitors available

Sign in to see all competitors

Sign In Create Free Account

Sources: Adaptimmune Therapeutics Plc’s official press releases and regulatory filings; CSIMarket.com’s market research; and the financial filings and press releases of other companies cited in this report.
Updated on:
Focus of this report: publicly traded companies.
For your research, we’ve provided 10 tables on Adaptimmune Therapeutics Plc versus competitors, including market share analysis.
You can find them in the navigation menu under Competition.
To download the tables, please subscribe.



Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.

© 2026 CSIMarket.com — Proprietary financial dataset. All rights reserved. Redistribution or automated extraction prohibited.